Literature DB >> 17503018

Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock.

Marc O Maybauer1,2, Dirk M Maybauer3,4, John F Fraser5, Lillian D Traber3, Martin Westphal3,6, Robert A Cox3, Ruksana Huda3, Yoshimitsu Y Nakano3, Perenlei Enkhbaatar3, Hal K Hawkins3, David N Herndon3, Daniel L Traber3.   

Abstract

OBJECTIVE: To investigate ceftazidime in acute lung injury (ALI) and sepsis. DESIGN AND
SETTING: Prospective, randomized, controlled animal study in an investigational ICU at a university hospital.
INTERVENTIONS: Eighteen female Merino sheep were prepared for chronic study and subjected to smoke inhalation and septic challenge according to an established protocol. MEASUREMENTS AND
RESULTS: Whereas global hemodynamics and oxygenation remained stable in sham animals (no injury, no treatment), the injury contributed to a hypotensive-hyperdynamic circulation in the control group (smoke inhalation and sepsis, no treatment), as indicated by a significant increase in cardiac index) and heart rate and a drop in mean arterial pressure. Treatment with ceftazidime (smoke inhalation and sepsis, treatment group) stabilized cardiac index and heart rate and attenuated the decrease in mean arterial pressure. The deterioration in PaO2/FiO2 ratio and pulmonary shunt fraction (Qs/Qt) was significantly delayed and blunted by ceftazidime. At 24 h after injury a significant increase in airway obstruction scores of bronchi and bronchioles in both injured groups was observed. Ceftazidime significantly reduced airway obstruction vs. control animals. Whereas plasma nitrate/nitrite levels increased similarly in the two injured groups, lung 3-nitrotyrosine content remained at the baseline level in the ceftazidime group.
CONCLUSIONS: In ovine lung injury ceftazidime improves global hemodynamics and oxygenation not only by bacterial clearance but also via reduction in toxic nitrogen species such as 3-nitrotyrosine. Therefore ceftazidime appears as a clinically relevant adjunct in the common setting of sepsis-associated lung injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503018     DOI: 10.1007/s00134-007-0658-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  38 in total

Review 1.  [Anti-Pseudomonas aerosol therapy in cystic fibrosis: improvement with tobramycin].

Authors:  P Foucaud; B Borel; O Charara; S Nathanson; P Petitprez; I Pin
Journal:  Rev Pneumol Clin       Date:  2002-06

2.  The ATP-sensitive potassium-channel inhibitor glibenclamide improves outcome in an ovine model of hemorrhagic shock.

Authors:  Dirk M Maybauer; John R Salsbury; Martin Westphal; Marc O Maybauer; Andrew L Salzman; Csaba Szabó; Beena B Westphal-Varghese; Lillian D Traber; Daniel L Traber
Journal:  Shock       Date:  2004-10       Impact factor: 3.454

3.  The risk of pneumonia in thermally injured patients requiring ventilatory support.

Authors:  L W Rue; W G Cioffi; A D Mason; W F McManus; B A Pruitt
Journal:  J Burn Care Rehabil       Date:  1995 May-Jun

4.  Gentamicin improves hemodynamics in ovine septic shock after smoke inhalation injury.

Authors:  Marc O Maybauer; Dirk M Maybauer; Lillian D Traber; Martin Westphal; Perenlei Enkhbaatar; Naoki Morita; Jeffrey M Jodoin; John P Heggers; David N Herndon; Daniel L Traber
Journal:  Shock       Date:  2005-09       Impact factor: 3.454

5.  The world according to poly(ADP-ribose) polymerase (PARP)--update 2006.

Authors:  Eberhard Barth; Peter Radermacher; Csaba Szabó
Journal:  Intensive Care Med       Date:  2006-08-23       Impact factor: 17.440

6.  Effect of antibiotics on polymorphonuclear neutrophil apoptosis.

Authors:  Daniel P Healy; Paul A Silverman; Alice N Neely; Ian Alan Holder; George E Babcock
Journal:  Pharmacotherapy       Date:  2002-05       Impact factor: 4.705

7.  Effects of manganese superoxide dismutase, when given after inhalation injury has been established.

Authors:  Hans G Bone; Heroiko Sakurai; Paul J Schenarts; Lillian D Traber; Daniel L Traber
Journal:  Crit Care Med       Date:  2002-04       Impact factor: 7.598

Review 8.  The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury.

Authors:  C Szabó
Journal:  Shock       Date:  1996-08       Impact factor: 3.454

Review 9.  Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.

Authors:  S P Conway; K G Brownlee; M Denton; D G Peckham
Journal:  Am J Respir Med       Date:  2003

10.  Oxygen consumption and electron spin resonance studies of free radical production by alveolar cells exposed to anoxia: inhibiting effects of the antibiotic ceftazidime.

Authors:  Ange Mouithys-Mickalad; Marianne Mathy-Hartert; Guanadu Du; Francis Sluse; Carol Deby; Maurice Lamy; Ginette Deby-Dupont
Journal:  Redox Rep       Date:  2002       Impact factor: 4.412

View more
  8 in total

1.  The peroxynitrite catalyst WW-85 improves microcirculation in ovine smoke inhalation injury and septic shock.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Andrew L Salzman; David N Herndon; Daniel L Traber
Journal:  Burns       Date:  2011-02-22       Impact factor: 2.744

2.  The peroxynitrite catalyst WW-85 improves pulmonary function in ovine septic shock.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Robert A Cox; Martin Westphal; Levente Kiss; Eszter M Horvath; Lillian D Traber; Hal K Hawkins; Andrew L Salzman; Garry J Southan; David N Herndon; Daniel L Traber
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

3.  A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.

Authors:  Yoshimitsu Nakano; Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Daniel L Traber
Journal:  Burns       Date:  2010-04-14       Impact factor: 2.744

Review 4.  Differentiated control of deranged nitric oxide metabolism: a therapeutic option in sepsis?

Authors:  Corinna Lupp; Silke Baasner; Can Ince; Frank Nocken; John F Stover; Martin Westphal
Journal:  Crit Care       Date:  2013-05-29       Impact factor: 9.097

5.  Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock.

Authors:  Marc O Maybauer; Dirk M Maybauer; John F Fraser; Csaba Szabo; Martin Westphal; Levente Kiss; Eszter M Horvath; Yoshimitsu Nakano; David N Herndon; Lillian D Traber; Daniel L Traber
Journal:  Crit Care       Date:  2010-11-26       Impact factor: 9.097

Review 6.  Optimal management of the critically ill: anaesthesia, monitoring, data capture, and point-of-care technological practices in ovine models of critical care.

Authors:  Saul Chemonges; Kiran Shekar; John-Paul Tung; Kimble R Dunster; Sara Diab; David Platts; Ryan P Watts; Shaun D Gregory; Samuel Foley; Gabriela Simonova; Charles McDonald; Rylan Hayes; Judith Bellpart; Daniel Timms; Michelle Chew; Yoke L Fung; Michael Toon; Marc O Maybauer; John F Fraser
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

7.  Pulmonary vascular permeability changes in an ovine model of methicillin-resistant Staphylococcus aureus sepsis.

Authors:  Collette C Jonkam; Kamna Bansal; Daniel L Traber; Atsumori Hamahata; Marc O Maybauer; Dirk M Maybauer; Robert A Cox; Matthias Lange; Rhykka L Connelly; Lillian D Traber; Clarisse D Djukom; John R Salsbury; David N Herndon; Perenlei Enkhbaatar
Journal:  Crit Care       Date:  2009-02-17       Impact factor: 9.097

Review 8.  Year in review in Intensive Care Medicine, 2007. I. Experimental studies. Clinical studies: brain injury and neurology, renal failure and endocrinology.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2008-01-04       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.